Registration Dossier

Administrative data

Description of key information

Key value for chemical safety assessment

Skin sensitisation

Endpoint conclusion
Endpoint conclusion:
adverse effect observed (sensitising)
Additional information:

According to the EU risk assessment report (2002) the following is noted in view of the two availabel skin sensitisation studies:

"Sensitising activity of DMS was tested in a murine local lymph node assay. Topical dosing of DMS (0.25, 0.5, and 1.0% in acetone/olive oil 80/20 v/v, number of animals not indicated) increased thymidine isotope incorporation in the lymph nodes more than 3-fold compared with vehicle-treated controls. A threefold increase was considered to be determinant of sensitising capacity (Ashby et al., 1995). It is noted that the positive response with DMS may be due to the corrosive properties. The Ear-Flank Test, however, showed an irregular reaction in a group of six guinea pigs treated with 10% DMS in olive oil. Interpretation of this result by the author was that DMS is a compound that does not cause sensitisation (Stevens, 1967). However this test is considered not suitable for evaluation, because the time between induction and challenge is considered to be too short."

However, due to the fact that a human case study with additional patch testing was made available by Yagami et al in 2009 (see 7.10.4) which havs been shown that DMS causes allergic contact dermatitis the classification of DMS as skin sensitiser.

Respiratory sensitisation

Endpoint conclusion
Additional information:

According to the EU risk assessment report, 2002:

There are neither data from human experience nor other indications for respiratory sensitisation. Therefore at present there is no need to request further information.

Justification for classification or non-classification

According to regulation (EC) 1272/2008 DMS has to be classified as "skin sens. 1" H317: May cause an allergic contact dermatitis.